Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA. Verma S, et al. Among authors: idorn t. JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080. JAMA Cardiol. 2019. PMID: 31721979 Free PMC article. Clinical Trial.
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann JFE, Persson F, Pratley RE, Rasmussen S, Rossing P, von Scholten BJ, Raz I; LEADER Trial Investigators. Mosenzon O, et al. Among authors: idorn t. Diabetes Obes Metab. 2020 Nov;22(11):2077-2088. doi: 10.1111/dom.14126. Epub 2020 Aug 7. Diabetes Obes Metab. 2020. PMID: 32618386 Free PMC article. Clinical Trial.
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Persson F, et al. Among authors: idorn t. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27. Diabetes Care. 2021. PMID: 33504496 Free PMC article. Clinical Trial.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V. Shaman AM, et al. Among authors: idorn t. Circulation. 2022 Feb 22;145(8):575-585. doi: 10.1161/CIRCULATIONAHA.121.055459. Epub 2021 Dec 14. Circulation. 2022. PMID: 34903039 Free PMC article. Clinical Trial.
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Mann JFE, et al. Among authors: idorn t. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4. Clin J Am Soc Nephrol. 2020. PMID: 32132141 Free PMC article. Clinical Trial.
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Mann JFE, et al. Among authors: idorn t. Circulation. 2019 May 28;139(22):e1017-e1018. doi: 10.1161/CIRCULATIONAHA.119.040419. Epub 2019 May 28. Circulation. 2019. PMID: 31136226 No abstract available.
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.
Idorn T, Knop FK, Jørgensen MB, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B. Idorn T, et al. Diabetes Care. 2016 Feb;39(2):206-13. doi: 10.2337/dc15-1025. Epub 2015 Aug 17. Diabetes Care. 2016. PMID: 26283739 Clinical Trial.
32 results